Synthetic Biologics, Inc. (SYN) Starts Presentation at Biotech Showcase Conference

Synthetic Biologics, Inc. (NYSE: SYN) is a clinical stage company developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. One of the company’s lead candidates in phase 2 development is SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD). For more information, visit the company’s website at www.syntheticbiologics.com.